2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Loriot Y, Petrylak D, Kalebasty A, Fléchon A, Jain R, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar A, Kyriakopoulos C, Pouessel D, Sternberg C, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa S. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals Of Oncology 2024, 35: 392-401. PMID: 38244927, DOI: 10.1016/j.annonc.2024.01.002.Peer-Reviewed Original ResearchAssociated with increased adverse eventsMetastatic urothelial carcinomaProgression-free survivalPlatinum-based chemotherapySacituzumab govitecanUGT1A1 statusFollow-upCohort 1Checkpoint inhibitorsOverall survivalUrothelial carcinomaAccelerated US Food and Drug Administration approvalPhase II open-label studyTreated with platinum-based chemotherapyMedian progression-free survivalUS Food and Drug Administration approvalActive metabolite of irinotecanFood and Drug Administration approvalIrinotecan-based therapyTreatment-related discontinuationsUridine diphosphate glucuronosyltransferase 1A1Metabolite of irinotecanInhibitor-based therapyDrug Administration approvalAntibody-drug conjugates
2015
The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra D, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. American Society Of Clinical Oncology Educational Book 2015, 92-103. PMID: 25993147, DOI: 10.14694/edbook_am.2015.35.92.Peer-Reviewed Original ResearchConceptsWD-NETsSite of originPD-NECsNeuroendocrine neoplasmsTreated with platinum-based chemotherapyFeatures of neuroendocrine neoplasmsTreatment of unresectable diseaseSpectrum of neuroendocrine tumorsAggressive clinical coursePlatinum-based chemotherapyFamily of neoplasmsUnresectable diseaseSurgical resectionNeuroendocrine differentiationNeuroendocrine tumorsNeuroendocrine phenotypeClinical courseProstate glandNeoplasia syndromeNon-neoplastic neuroendocrine cellsHistological classificationGenetic alterationsClinical managementAnatomical sitesHistological evidence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply